anti-HQNO monoclonal antibody

The anti-HQNO monoclonal antibody is a preclinical-stage biologic developed by the Institute for Advanced Chemistry of Catalonia (IQAC-CSIC) and the Networking Research Center for Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN). It is designed to target and neutralize 2-heptyl-4-quinoline N-oxide (HQNO), a key quorum sensing-regulated virulence factor produced by Pseudomonas aeruginosa. By binding to HQNO, the antibody acts as a quencher to disrupt bacterial communication, attenuate virulence, and prevent biofilm formation without directly affecting bacterial growth. In vitro studies have demonstrated that co-treatment with this monoclonal antibody provides complete protection to host cells (such as murine macrophages) against HQNO-induced cytotoxicity and restores cytokine production to near baseline levels, highlighting its potential as an innovative therapeutic approach for Pseudomonas aeruginosa infections.

Other names

anti-2-heptyl-4-quinoline N-oxide mAbanti2-heptyl-4-quinoline N-oxide mAbanti 2-heptyl-4-quinoline N-oxide mAbanti-2-heptyl-4-quinoline N-oxide monoclonal antibodyanti2-heptyl-4-quinoline N-oxide monoclonal antibodyanti 2-heptyl-4-quinoline N-oxide monoclonal antibodyanti-HQNO mAb